X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA CADILA HEALTHCARE ELDER PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x -0.2 33.1 - View Chart
P/BV x 0.1 8.5 1.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
CADILA HEALTHCARE
Mar-16
ELDER PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs380454 83.6%   
Low Rs188305 61.7%   
Sales per share (Unadj.) Rs491.296.1 511.2%  
Earnings per share (Unadj.) Rs-3.214.9 -21.4%  
Cash flow per share (Unadj.) Rs14.417.8 80.8%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.552.3 720.2%  
Shares outstanding (eoy) m20.541,023.74 2.0%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x0.63.9 14.6%   
Avg P/E ratio x-89.325.5 -349.9%  
P/CF ratio (eoy) x19.721.3 92.6%  
Price / Book Value ratio x0.87.3 10.4%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m5,833388,458 1.5%   
No. of employees `000NA15.4 0.0%   
Total wages/salary Rs m2,17913,317 16.4%   
Avg. sales/employee Rs ThNM6,371.1-  
Avg. wages/employee Rs ThNM862.4-  
Avg. net profit/employee Rs ThNM986.1-  
INCOME DATA
Net Sales Rs m10,08998,376 10.3%  
Other income Rs m257941 27.3%   
Total revenues Rs m10,34699,317 10.4%   
Gross profit Rs m-79223,829 -3.3%  
Depreciation Rs m3613,022 12.0%   
Interest Rs m2,756486 567.1%   
Profit before tax Rs m-3,65321,262 -17.2%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m3,713-25 -14,850.8%   
Tax Rs m1255,716 2.2%   
Profit after tax Rs m-6515,226 -0.4%  
Gross profit margin %-7.824.2 -32.4%  
Effective tax rate %-3.426.9 -12.7%   
Net profit margin %-0.615.5 -4.2%  
BALANCE SHEET DATA
Current assets Rs m9,24044,376 20.8%   
Current liabilities Rs m9,99834,071 29.3%   
Net working cap to sales %-7.510.5 -71.7%  
Current ratio x0.91.3 71.0%  
Inventory Days Days4654 86.0%  
Debtors Days Days6062 96.1%  
Net fixed assets Rs m10,12447,896 21.1%   
Share capital Rs m2061,024 20.1%   
"Free" reserves Rs m5,58248,746 11.5%   
Net worth Rs m7,73453,519 14.5%   
Long term debt Rs m4,8898,964 54.5%   
Total assets Rs m22,882100,163 22.8%  
Interest coverage x-0.344.7 -0.7%   
Debt to equity ratio x0.60.2 377.4%  
Sales to assets ratio x0.41.0 44.9%   
Return on assets %11.815.7 75.0%  
Return on equity %-0.828.4 -3.0%  
Return on capital %22.334.3 65.1%  
Exports to sales %3.045.3 6.7%   
Imports to sales %0.45.9 7.2%   
Exports (fob) Rs m30744,537 0.7%   
Imports (cif) Rs m435,838 0.7%   
Fx inflow Rs m30744,881 0.7%   
Fx outflow Rs m1259,069 1.4%   
Net fx Rs m18135,812 0.5%   
CASH FLOW
From Operations Rs m11,75419,938 59.0%  
From Investments Rs m-561-9,039 6.2%  
From Financial Activity Rs m-6,762-9,527 71.0%  
Net Cashflow Rs m4,4321,372 323.0%  

Share Holding

Indian Promoters % 39.6 74.8 52.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 8.3 90.4%  
FIIs % 16.8 5.9 284.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 11.0 328.2%  
Shareholders   16,479 44,069 37.4%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   SUN PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - GLENMARK PHARMA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS